The search for valid instruments to measure different domains of health disturbances becomes increasingly important for the assessment of Parkinson’s disease. The most widely used tool is the Unified Parkinson’s Disease Rating Scale (UPDRS) which was introduced in 1987 and is currently awaiting revision. In addition, a variety of instruments have been used to capture non-motor aspects of Parkinson’s disease but only a minority of these instruments has been validated for this particular disease condition. Measurements of quality of life are being incorporated into an increasing number of studies in order to reflect a more integral view of health and have contributed to a better understanding of the impact of disease and interventions. The International Classification of Functioning, Disability and Health introduced by the WHO in 2001 offers a multidimensional approach to human functioning and participation that can also be applied to the assessment of health status in PD. This workshop report will focus on the present state of clinimetry in PD and discuss future perspectives.
Key wordsParkinson’s disease scales UPDRS ICF quality of life
- 2.Fahn S, Elton RL (1987) UPDRS program members Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB (eds) Recent developments in Parkinson’s disease, vol. 2, Macmillanm Healthcare Information, Florham Park, pp 153–163Google Scholar
- 9.Miyasaki JM, Shannon K, Voon V, et al. (2006) Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:996–1002PubMedCrossRefGoogle Scholar
- 11.Peto V, Jenkinson C (1999) Quality of life measures in Parkinson’s disease. In: Martín PM, Koller WC (eds) Quality of life in Parkinson’s disease. Masson S. A., Barcelona, pp 37–54Google Scholar
- 12.Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M (2002) Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled doubleblind study in Germany and Austria (Celomen study). Acta Neurol Scand 105(4):245–255PubMedCrossRefGoogle Scholar
- 19.Schrag A, Sampaio C, Counsell N, Poewe W (2006) Minimal clinically important change of the Unified Parkinson’s Disease Rating Scale. Mov Disord, (in press) DOI 10.1002/mds.20914Google Scholar
- 20.World Health Organization (2002) Towards a Common Language for Function Disability and Health. Geneva. www.who.int/icfGoogle Scholar